×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
URGN – urogen pharma ltd. - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
URGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/25
09:08 am
urgn
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/25
08:00 am
urgn
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
Low
Report
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
11/16
10:26 pm
urgn
UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs [Yahoo! Finance]
Low
Report
UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs [Yahoo! Finance]
11/9
08:55 am
urgn
Analysts Have Made A Financial Statement On UroGen Pharma Ltd.'s (NASDAQ:URGN) Third-Quarter Report [Yahoo! Finance]
Low
Report
Analysts Have Made A Financial Statement On UroGen Pharma Ltd.'s (NASDAQ:URGN) Third-Quarter Report [Yahoo! Finance]
11/6
10:28 pm
urgn
UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/6
04:40 pm
urgn
UroGen Pharma Ltd (URGN) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... [Yahoo! Finance]
Low
Report
UroGen Pharma Ltd (URGN) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... [Yahoo! Finance]
11/6
08:00 am
urgn
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
High
Report
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
11/6
07:58 am
urgn
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
High
Report
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
08:00 am
urgn
urogen pharma ltd. - ordinary shares
BEAT
Report
30.0%
urogen pharma ltd. - ordinary shares
8/7/2025
08:00 am
urgn
urogen pharma ltd. - ordinary shares
MISS
Report
-7.6%
urogen pharma ltd. - ordinary shares
5/12/2025
08:00 am
urgn
urogen pharma ltd. - ordinary shares
MISS
Report
12.5%
urogen pharma ltd. - ordinary shares
3/10/2025
08:00 am
urgn
urogen pharma ltd. - ordinary shares
MISS
Report
-3.8%
urogen pharma ltd. - ordinary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/1
04:52 pm
urgn
Form 4 UroGen Pharma Ltd. For: Nov 26 Filed by: BUTITTA CYNTHIA M
High
Report
Form 4 UroGen Pharma Ltd. For: Nov 26 Filed by: BUTITTA CYNTHIA M
12/1
04:48 pm
urgn
Form 4 UroGen Pharma Ltd. For: Nov 26 Filed by: Robinson James A. Jr.
High
Report
Form 4 UroGen Pharma Ltd. For: Nov 26 Filed by: Robinson James A. Jr.
12/1
04:46 pm
urgn
Form 4 UroGen Pharma Ltd. For: Nov 26 Filed by: WEN LEANA
High
Report
Form 4 UroGen Pharma Ltd. For: Nov 26 Filed by: WEN LEANA
12/1
04:45 pm
urgn
Form 4 UroGen Pharma Ltd. For: Nov 26 Filed by: Wildman Daniel George
High
Report
Form 4 UroGen Pharma Ltd. For: Nov 26 Filed by: Wildman Daniel George
11/20
01:42 pm
urgn
Form 4 UroGen Pharma Ltd. For: Nov 19 Filed by: Schoenberg Mark
Low
Report
Form 4 UroGen Pharma Ltd. For: Nov 19 Filed by: Schoenberg Mark
11/19
03:20 pm
urgn
Form 144 UroGen Pharma Ltd. Filed by: Schoenberg Mark
Low
Report
Form 144 UroGen Pharma Ltd. Filed by: Schoenberg Mark
11/14
04:37 pm
urgn
Form SCHEDULE 13G/A UroGen Pharma Ltd. Filed by: Paradigm Biocapital Advisors LP
Low
Report
Form SCHEDULE 13G/A UroGen Pharma Ltd. Filed by: Paradigm Biocapital Advisors LP
11/14
11:27 am
urgn
Form SCHEDULE 13G UroGen Pharma Ltd. Filed by: TORONTO DOMINION BANK
Low
Report
Form SCHEDULE 13G UroGen Pharma Ltd. Filed by: TORONTO DOMINION BANK
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/23
Form 8-K UroGen Pharma Ltd. For: Mar 20
18.6%
11/12 Q3/2019 9/30/2019 EPS -1.060 ZacksConsensus -1.260 ActVsEst 0.200 - Beat 13.6%
4/13 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. 11.3%
4/17 Urogen Pharma Ltd (NASDAQ: URGN) had its price target raised by analysts at Oppenheimer Holdings Inc. from $45.00 to $47.00. They now have an "outperform" rating on the stock. 9.9%
4/16 UruGen shares jump 10% on FDA approval of rare cancer treatment [MarketWatch] 9.6%
4/3 UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer 8.1%
11/18 Form 4 UroGen Pharma Ltd. For: Nov 14 Filed by: Mullennix Stephen 8.0%
12/6 UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 6.7%
2/14 Form SC 13G/A UroGen Pharma Ltd. Filed by: Wildcat Capital Management, LLC 6.6%
1/16 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at Cowen Inc. 6.5%
11/12 Q3/2019 9/30/2019 EPS -1.060 ZacksConsensus -1.260 ActVsEst 0.200 - Beat 13.6%
4/13 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. 11.3%
4/17 Urogen Pharma Ltd (NASDAQ: URGN) had its price target raised by analysts at Oppenheimer Holdings Inc. from $45.00 to $47.00. They now have an "outperform" rating on the stock. 9.9%
4/16 UruGen shares jump 10% on FDA approval of rare cancer treatment [MarketWatch] 9.6%
4/3 UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer 8.1%
11/18 Form 4 UroGen Pharma Ltd. For: Nov 14 Filed by: Mullennix Stephen 8.0%
12/6 UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 6.7%
2/14 Form SC 13G/A UroGen Pharma Ltd. Filed by: Wildcat Capital Management, LLC 6.6%
1/16 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at Cowen Inc. 6.5%
TOP News Decliners
9/24
Form 8-K UroGen Pharma Ltd. For: Sep 24
-19.9%
4/30 The Lancet Oncology Publishes Details of UroGen Pharma’s Pivotal OLYMPUS Trial -12.2%
4/16 Form 8-K UroGen Pharma Ltd. For: Apr 15 -7.8%
2/12 Form SC 13D/A UroGen Pharma Ltd. Filed by: Arkin Moshe -5.3%
11/12 UroGen Pharma Ltd. (URGN) Q3 2019 Earnings Call Transcript [The Motley Fool] -4.9%
8/5 UroGen Pharma to Report Second Quarter 2019 Financial Results on Friday, August 9, 2019 -4.7%
5/11 UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -4.6%
5/28 Form 8-K UroGen Pharma Ltd. For: May 21 -4.5%
9/26 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at Cowen Inc. -4.4%
5/9 UroGen Pharma Ltd. (URGN) Q1 2019 Earnings Call Transcript [The Motley Fool] -3.1%
4/30 The Lancet Oncology Publishes Details of UroGen Pharma’s Pivotal OLYMPUS Trial -12.2%
4/16 Form 8-K UroGen Pharma Ltd. For: Apr 15 -7.8%
2/12 Form SC 13D/A UroGen Pharma Ltd. Filed by: Arkin Moshe -5.3%
11/12 UroGen Pharma Ltd. (URGN) Q3 2019 Earnings Call Transcript [The Motley Fool] -4.9%
8/5 UroGen Pharma to Report Second Quarter 2019 Financial Results on Friday, August 9, 2019 -4.7%
5/11 UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -4.6%
5/28 Form 8-K UroGen Pharma Ltd. For: May 21 -4.5%
9/26 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at Cowen Inc. -4.4%
5/9 UroGen Pharma Ltd. (URGN) Q1 2019 Earnings Call Transcript [The Motley Fool] -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: